Study of evaluating the efficacy of microneedle may reduce the injection pain of the melanoma patinet receiving interferon-beta as an adjuvant therapy

Study of evaluating the efficacy of microneedle may reduce the injection pain of the melanoma patinet receiving interferon-beta as an adjuvant therapy - interferon and microneedle

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013505

Enrollment

Registered

2014-04-01

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma patient receiving intradermal injection of interferon-beta as adjuvant therapy

Interventions

Using 34G microneedle 29G insulin injector

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient using interferon-beta as an adjuvant therapy of malignant melanoma

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Visual analogue scale	—

Countries

Japan

Contacts

Public ContactYasuhiro Fujisawa

University of Tsukuba Dermatology

fujisan@md.tsukuba.ac.jp0298533128

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026